FATE vs. MESO, EXAI, VALN, NVAX, ALEC, TSHA, EDIT, ALLO, CCCC, and TRML
Should you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Mesoblast (MESO), Exscientia (EXAI), Valneva (VALN), Novavax (NVAX), Alector (ALEC), Taysha Gene Therapies (TSHA), Editas Medicine (EDIT), Allogene Therapeutics (ALLO), C4 Therapeutics (CCCC), and Tourmaline Bio (TRML). These companies are all part of the "biological products, except diagnostic" industry.
Fate Therapeutics (NASDAQ:FATE) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, community ranking, valuation, dividends and risk.
Fate Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Mesoblast has a beta of 3.59, suggesting that its share price is 259% more volatile than the S&P 500.
In the previous week, Fate Therapeutics had 2 more articles in the media than Mesoblast. MarketBeat recorded 6 mentions for Fate Therapeutics and 4 mentions for Mesoblast. Fate Therapeutics' average media sentiment score of 0.83 beat Mesoblast's score of -0.04 indicating that Fate Therapeutics is being referred to more favorably in the media.
Mesoblast has a net margin of 0.00% compared to Fate Therapeutics' net margin of -253.30%. Mesoblast's return on equity of 0.00% beat Fate Therapeutics' return on equity.
Mesoblast has lower revenue, but higher earnings than Fate Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fate Therapeutics currently has a consensus price target of $6.73, indicating a potential upside of 40.74%. Mesoblast has a consensus price target of $13.67, indicating a potential upside of 147.14%. Given Mesoblast's stronger consensus rating and higher possible upside, analysts clearly believe Mesoblast is more favorable than Fate Therapeutics.
Fate Therapeutics received 75 more outperform votes than Mesoblast when rated by MarketBeat users. However, 70.70% of users gave Mesoblast an outperform vote while only 69.18% of users gave Fate Therapeutics an outperform vote.
97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 5.0% of Fate Therapeutics shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Mesoblast beats Fate Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Fate Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fate Therapeutics Competitors List
Related Companies and Tools
